CU
CURE.XETRA VanEck Genomics and Healthcare Innovators UCITS ETF EUR
- EUR
No recent price
- Total assets
- 24.4M
- Expense ratio
- -
- Dividend yield
- 0.09%
- 1-year return
- +33.94%
- Holdings
- 10
- Since
- 2022
Fund data as reported by the issuer, updated Nov 6, 2026. Total assets are in the fund's base currency.
What does CURE.XETRA invest in?
Tracks Morningstar Gbl Health NR USD- Mostly US stocks (91.5%)
- Largest sector: Healthcare (96.2%)
- Largest region: North America (91.5%)
- Top 3 holdings: 23.3% of the fund
Asset allocation
- US stocks 91.5%
- Non-US stocks 9.4%
Top holdings
- Moderna Inc 8.91%
- Vertex Pharmaceuticals Inc 7.63%
- Regeneron Pharmaceuticals Inc 6.81%
- Natera Inc 6.60%
- Veeva Systems Inc Class A 6.32%
VanEck Genomics and Healthcare Innovators UCITS ETF EUR performance
Sharpe ratio 0.84- This year
- +31.05%
- 1 year
- +33.94%
- 3 years
- +15.20%
- 5 years
- 0.00%
Volatility 24.5% over 1 year and 19.5% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
CURE.XETRA price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
VanEck Genomics and Healthcare Innovators UCITS ETF EUR top holdings
59.3% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Moderna Inc MRNA.US | Healthcare | United States | 8.91% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 7.63% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 6.81% |
| Natera Inc NTRA.US | Healthcare | United States | 6.60% |
| Veeva Systems Inc Class A VEEV.US | Healthcare | United States | 6.32% |
| Illumina Inc ILMN.US | Healthcare | United States | 5.96% |
| DexCom Inc DXCM.US | Healthcare | United States | 4.93% |
| Guardant Health Inc GH.US | Healthcare | United States | 4.51% |
| BioNTech SE BNTX.US | Healthcare | United States | 3.86% |
| Alnylam Pharmaceuticals Inc ALNY.US | Healthcare | United States | 3.75% |
CURE.XETRA sector exposure
- Healthcare96.2%
Share of the stocks in the fund.
CURE.XETRA regional exposure
- North America91.5%
- Europe Developed3.0%
- Asia Emerging2.5%
- Australasia2.3%
- Japan1.4%
- United Kingdom0.5%
Share of the stocks in the fund.
Company size
Average market cap 24.4B- Big cap20.9%
- Medium cap46.6%
- Small cap26.7%
- Micro cap4.4%
VanEck Genomics and Healthcare Innovators UCITS ETF EUR fund profile
- Fund name
- VanEck Genomics and Healthcare Innovators UCITS ETF EUR
- Ticker
- CURE.XETRA
- Exchange
- XETRA Stock Exchange
- Index tracked
- Morningstar Gbl Health NR USD
- Category
- Healthcare Equity
- Domicile
- Irland
- Inception date
- Sep 2, 2022
- Trading currency
- EUR
- Expense ratio
- -